LIPO (Lipella Pharmaceuticals) Debt-to-Asset : 0.11 (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Lipella Pharmaceuticals Debt-to-Asset?

Lipella Pharmaceuticals LIPO Debt-to-Asset is 0.11 as of Sep. 2025. The stock has 1 warning sign investors should review.

Lipella Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2025 was $0.04 Mil. Lipella Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2025 was $0.22 Mil. Lipella Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2025 was $2.35 Mil. Lipella Pharmaceuticals's debt to asset for the quarter that ended in Sep. 2025 was 0.11.

Lipella Pharmaceuticals  (OTCPK:LIPO) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Lipella Pharmaceuticals Debt-to-Asset Related Terms

Lipella Pharmaceuticals Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Lipella Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lipella Pharmaceuticals Debt-to-Asset Chart

Lipella Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Asset
0.41 0.14 0.07 0.04 0.02

Lipella Pharmaceuticals Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.02 0.01 0.07 0.11

LIPO vs SIGY, CNBX, CARM: Debt-to-Asset Comparison

For the Biotechnology subindustry, Lipella Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lipella Pharmaceuticals Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipella Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Lipella Pharmaceuticals's Debt-to-Asset falls into.


Lipella Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Lipella Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.048 + 0) / 2.674
=0.02

Lipella Pharmaceuticals's Debt-to-Asset for the quarter that ended in Sep. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.044 + 0.22) / 2.35
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.11 mean?
Lipella Pharmaceuticals (LIPO) has a Debt-to-Asset of 0.11 as of Sep. 2025. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Lipella Pharmaceuticals and its competitors.
Is Lipella Pharmaceuticals' Debt-to-Asset too high?
Lipella Pharmaceuticals' current Debt-to-Asset is 0.11.
How does Lipella Pharmaceuticals' Debt-to-Asset compare to SIGY and CNBX?
Lipella Pharmaceuticals' Debt-to-Asset of 0.11 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Lipella Pharmaceuticals and its competitors. Lipella Pharmaceuticals's current Debt-to-Asset is 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipella Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Lipella Pharmaceuticals (LIPO) is currently considered Possible Value Trap. The stock's GF Value™ is $8.83, compared to a current price of $0.00 — trading 100% below its estimated fair value. The current Debt-to-Asset is 0.11. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Lipella Pharmaceuticals (LIPO), the current Debt-to-Asset is 0.11 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lipella Pharmaceuticals Business Description

Address 7800 Susquehanna Street, Suite 505, Pittsburgh, PA, USA, 15208
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410, which can be helpful in the treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.